A multicentre validation study of the diagnostic value of plasma neurofilament light
Open Access
- 7 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-12
- https://doi.org/10.1038/s41467-021-23620-z
Abstract
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King’s College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.This publication has 68 references indexed in Scilit:
- Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyEBioMedicine, 2015
- Increased CSF biomarkers of angiogenesis in Parkinson diseaseNeurology, 2015
- Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer diseaseNeurology, 2015
- The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's diseaseNeuroscience Letters, 2014
- Diffusion Tensor Tractography versus Volumetric Imaging in the Diagnosis of Behavioral Variant Frontotemporal DementiaPLOS ONE, 2013
- Amyloid vs FDG-PET in the differential diagnosis of AD and FTLDNeurology, 2011
- AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2009
- Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotypeEuropean Journal of Neurology, 2007
- Neurochemical Aftermath of Amateur BoxingArchives of Neurology, 2006
- Axonal damage markers in cerebrospinal fluid are increased in ALSNeurology, 2006